Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SAN DIEGO, Oct. 27, 2016 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended September 30, 2016, before the opening of trading on Thursday, November 3, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, November 3. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (785) 830-7992 (preferred), or (800) 768-6569 (toll-free), and reference confirmation code 1380572. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 1380572. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Contact: Andrew Hopkins (858) 646-1127 Website: www.vical.com
